Latest revenue
$353.4K
as of 2026-03-31
Latest net income
$-2.2M
as of 2026-03-31
Net margin
-615.4%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $10.4M
- Enterprise value
- $10.4M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $50.00
- 52-wk low
- $0.90
- Beta
- —
- Shares out
- 10.6M
5-year trend
What this company does
ITEM 1.BUSINESS. Overview We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that was launched in February 2026 (the Longevity test is also being branded “OneTest for Workplace Wellness” when marketed to self-insured employers). Both tests are run in our CAP (College of American Pathologists) accredited, CLIA (Clinical Laboratory Improvement Amendments) licensed laboratory in Gaithersburg, MD. This…
AI summary unavailable — showing raw filing excerpt
Generated from AIDX's filing dated 2026-03-31
Key risks
ITEM 1A.RISK FACTORS. An investment in our securities involves a high degree of risk. You should carefully read and consider all of the risks described below, together with all of the other information contained or referred to in this report, before making an investment decision with respect to our securities. If any of the following events occur, our financial condition, business and results of operations (including cash flows) may be materially adversely affected. In that event, the market price of our shares could decline, and you could lose all or part of your investment. Risks Related to Our Business and Industry With limited exceptions, we have incurred losses since our inception, and…
AI summary unavailable — showing raw filing excerpt
Generated from AIDX's filing dated 2026-03-31
Profitability
Gross margin
29.6%
43.8%Operating margin
-162.9%
49.7%Net margin
-182.8%
42.3%Return on equity
19447.7%
5373.8%Return on assets
-90.4%
41.7%Leverage
Debt / equity
-216.21×
15756.9%Long-term debt / equity
-32.22×
Debt / assets
100.5%
73.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $353.4K | -36.2% | $-2.2M | -184.4% | -615.4% |
Q1 2025 2025-03-31 | $553.8K | — | $-764.6K | — | -138.1% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Testing Laboratories · SIC 8734
Your notes
Keep private notes on AIDX — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$0
Net activity
+$0
Distinct insiders
0
Open-market trades over the last 365 days.
Recent transactions
| Date | Insider | Type | Shares | Price | Value |
|---|
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns AIDX
Institutional value
$15.9K
Total shares held
8.5K
Distinct holders
2
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | UBS Group AG | 8.3K | $15.6K | — | New |
| 2 | TOTH FINANCIAL ADVISORY CORP | 157 | $296 | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once AIDX's latest filing finishes processing.